EVAX logo

Evaxion Biotech A/S (EVAX) Stock

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

Denmark

IPO:

05 February 2021

Indexes:

Not included

Description:

Evaxion Biotech A/S is a biotechnology company focused on developing innovative immunotherapies and vaccines. Using advanced artificial intelligence, they create personalized treatments for cancer and infectious diseases, aiming to improve patient outcomes and enhance the effectiveness of existing therapies.

Events Calendar

Earnings

Next earnings date:

Mar 27, 2025

Recent quarterly earnings:

Oct 31, 2024

Recent annual earnings:

Mar 27, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

Jan 22, 2024

Analyst ratings

Recent major analysts updates

01 Nov '24 HC Wainwright & Co.
Buy
26 Sept '24 HC Wainwright & Co.
Buy
20 Sept '24 HC Wainwright & Co.
Buy
16 Aug '24 HC Wainwright & Co.
Buy
01 Aug '24 HC Wainwright & Co.
Buy
04 June '24 HC Wainwright & Co.
Buy
03 Apr '24 HC Wainwright & Co.
Buy
02 Apr '24 Ladenburg Thalmann
Buy
20 Mar '24 HC Wainwright & Co.
Buy
12 Feb '24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Evaxion to announce business update and third quarter 2024 financial results on October 31
Evaxion to announce business update and third quarter 2024 financial results on October 31
Evaxion to announce business update and third quarter 2024 financial results on October 31
EVAX
globenewswire.com28 October 2024

COPENHAGEN, Denmark, October 28, 2024 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its third quarter 2024 financial results on Thursday October 31, 2024, before opening of the Nasdaq CM.

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials
Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials
Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials
EVAX
globenewswire.com09 October 2024

COPENHAGEN, Denmark, October 9, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, has now evidence from three different clinical trials validating the vaccine target predictions of its AI platform.

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform
EVAX
globenewswire.com03 October 2024

COPENHAGEN, Denmark, October 3, 2024 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, continues to gather clinical evidence for the steady improvement of its AI-Immunology™ platform.

Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
Evaxion launches improved AI-Immunology™ platform for vaccine antigen prediction
EVAX
globenewswire.com19 September 2024

COPENHAGEN, Denmark, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, launches an enhanced version of its clinically validated AI-Immunology™ platform with an update of its EDEN™ AI prediction model. Among other improvements, the model can now predict toxin antigens, allowing for the development of improved bacterial vaccines.

Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript
Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript
Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Call Transcript
EVAX
seekingalpha.com14 August 2024

Evaxion Biotech A/S (EVAX) Q2 2024 Earnings Conference Call August 14, 2024 8:30 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rono - Chief Scientific Officer Jesper Nissen - Chief Operating Officer and Chief Financial Officer Mads Kronborg - Vice President, Investor Relations & Communication Conference Call Participants Li Chen - H.C. Wainwright Thomas Flaten - Lake Street Capital Markets Chong Liu - Ladenburg Operator Good day and thank you for standing by.

Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
Evaxion to Announce Business Update and Second Quarter 2024 Financial Results on August 14
EVAX
globenewswire.com12 August 2024

COPENHAGEN, Denmark, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its second quarter 2024 financial results on Wednesday, August 14, 2024, before opening of the Nasdaq-CM.

Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
Evaxion Reinforces Milestone Timeline and Provides Shareholder Update
EVAX
globenewswire.com03 July 2024

COPENHAGEN, Denmark, July 03, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, today issued the following letter to shareholders.

Evaxion Announces Business Update and First Quarter 2024 Financial Results
Evaxion Announces Business Update and First Quarter 2024 Financial Results
Evaxion Announces Business Update and First Quarter 2024 Financial Results
EVAX
globenewswire.com28 May 2024

COPENHAGEN, Denmark, May 28, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, provides business update and announces first quarter 2024 financial results.

Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
Evaxion (EVAX) Up on Upbeat Preclinical S. Aureus Vaccine Data
EVAX
Zacks Investment Research03 April 2024

Evaxion (EVAX) gains 20% on positive results from the pre-clinical studies of its EVX-B1 vaccine candidate in large non-rodent animals, which is being developed to treat S. aureus infection.

Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript
Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript
Evaxion Biotech A/S (EVAX) Q4 2023 Earnings Call Transcript
EVAX
Seeking Alpha02 April 2024

Evaxion Biotech A/S (EVAX) Q4 2023 Results Conference Call April 2, 2024 9:00 AM ET Company Participants Christian Kanstrup - Chief Executive Officer Birgitte Rono - Chief Scientific Officer Jesper Nissen - Chief Operating Officer and Chief Financial Officer Conference Call Participants Ahu Demir - Ladenburg Thalmann Swayampakula Ramakanth - H.C. Wainwright Thomas Flaten - Lake Street Capital Markets Richard Ramanius - Redeye Christian Kanstrup Hello, everyone, and a very warm welcome to this Evaxion Business Update Conference call on the back of our Full Year 2023 Results.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the primary business of Evaxion Biotech A/S?
  • What is the ticker symbol for Evaxion Biotech A/S?
  • Does Evaxion Biotech A/S pay dividends?
  • What sector is Evaxion Biotech A/S in?
  • What industry is Evaxion Biotech A/S in?
  • What country is Evaxion Biotech A/S based in?
  • When did Evaxion Biotech A/S go public?
  • Is Evaxion Biotech A/S in the S&P 500?
  • Is Evaxion Biotech A/S in the NASDAQ 100?
  • Is Evaxion Biotech A/S in the Dow Jones?
  • When was Evaxion Biotech A/S's last earnings report?
  • When does Evaxion Biotech A/S report earnings?
  • Should I buy Evaxion Biotech A/S stock now?

What is the primary business of Evaxion Biotech A/S?

Evaxion Biotech A/S is a biotechnology company focused on developing innovative immunotherapies and vaccines. Using advanced artificial intelligence, they create personalized treatments for cancer and infectious diseases, aiming to improve patient outcomes and enhance the effectiveness of existing therapies.

What is the ticker symbol for Evaxion Biotech A/S?

The ticker symbol for Evaxion Biotech A/S is NASDAQ:EVAX

Does Evaxion Biotech A/S pay dividends?

No, Evaxion Biotech A/S does not pay dividends

What sector is Evaxion Biotech A/S in?

Evaxion Biotech A/S is in the Healthcare sector

What industry is Evaxion Biotech A/S in?

Evaxion Biotech A/S is in the Biotechnology industry

What country is Evaxion Biotech A/S based in?

Evaxion Biotech A/S is headquartered in Denmark

When did Evaxion Biotech A/S go public?

Evaxion Biotech A/S's initial public offering (IPO) was on 05 February 2021

Is Evaxion Biotech A/S in the S&P 500?

No, Evaxion Biotech A/S is not included in the S&P 500 index

Is Evaxion Biotech A/S in the NASDAQ 100?

No, Evaxion Biotech A/S is not included in the NASDAQ 100 index

Is Evaxion Biotech A/S in the Dow Jones?

No, Evaxion Biotech A/S is not included in the Dow Jones index

When was Evaxion Biotech A/S's last earnings report?

Evaxion Biotech A/S's most recent earnings report was on 31 October 2024

When does Evaxion Biotech A/S report earnings?

The next expected earnings date for Evaxion Biotech A/S is 27 March 2025

Should I buy Evaxion Biotech A/S stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions